Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy
Melhem Solh, Sophia Yohe, Daniel Weisdorf, et al.
American Journal of Hematology (2014) Vol. 89, Iss. 12, pp. 1121-1131
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Molecular biomarkers in acute myeloid leukemia
Jeanette Prada-Arismendy, Johanna C. Arroyave-Ospina, Sarah Röthlisberger
Blood Reviews (2016) Vol. 31, Iss. 1, pp. 63-76
Closed Access | Times Cited: 276
The proteogenomic subtypes of acute myeloid leukemia
Ashok Kumar Jayavelu, Sebastian Wolf, Florian Buettner, et al.
Cancer Cell (2022) Vol. 40, Iss. 3, pp. 301-317.e12
Open Access | Times Cited: 97
Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia
Shunjie Yu, Sen Yang, Lijuan Hu, et al.
Annals of Hematology (2025)
Open Access | Times Cited: 1
The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders
Robert Roskoski
Pharmacological Research (2018) Vol. 133, pp. 35-52
Closed Access | Times Cited: 70
Extramedullary acute myelogenous leukemia
Melhem Solh, Scott R. Solomon, Lawrence E. Morris, et al.
Blood Reviews (2016) Vol. 30, Iss. 5, pp. 333-339
Closed Access | Times Cited: 62
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801
Guido Marcucci, Susan M. Geyer, Kristina Laumann, et al.
Blood Advances (2020) Vol. 4, Iss. 4, pp. 696-705
Open Access | Times Cited: 59
miR-139-5p controls translation in myeloid leukemia through EIF4G2
Stephan Emmrich, F Engeland, Mona El-Khatib, et al.
Oncogene (2015) Vol. 35, Iss. 14, pp. 1822-1831
Open Access | Times Cited: 64
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
Se young Han, Krzysztof Mrózek, Jenna Voutsinas, et al.
Blood Advances (2021) Vol. 5, Iss. 10, pp. 2481-2489
Open Access | Times Cited: 37
Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
Jessica M. Salmon, Izabela Todorovski, Kym L. Stanley, et al.
Cancer Discovery (2022) Vol. 12, Iss. 6, pp. 1560-1579
Open Access | Times Cited: 25
Myeloid sarcoma: more and less than a distinct entity
Giuseppe Gaetano Loscocco, Alessandro M. Vannucchi
Annals of Hematology (2023) Vol. 102, Iss. 8, pp. 1973-1984
Open Access | Times Cited: 16
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities
Chandrima Sinha, Lea Cunningham, Paul Liu
Seminars in Hematology (2015) Vol. 52, Iss. 3, pp. 215-222
Open Access | Times Cited: 41
Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome
Chae‐Yin Cher, GM Leung, Chun Hang Au, et al.
Blood Cancer Journal (2016) Vol. 6, Iss. 7, pp. e442-e442
Open Access | Times Cited: 39
Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study
Heesun J. Rogers, Xiaoqiong Wang, Yan Xie, et al.
American Journal of Hematology (2020) Vol. 95, Iss. 7, pp. 799-808
Open Access | Times Cited: 36
Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia
Celalettin Üstün, Guido Marcucci
Current Opinion in Hematology (2015) Vol. 22, Iss. 2, pp. 85-91
Closed Access | Times Cited: 37
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Sara Tarantino, M. Labopin, Robert Zeiser, et al.
Bone Marrow Transplantation (2025)
Closed Access
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors
Nicolas Duployez, Christophe Willekens, Alice Marceau‐Renaut, et al.
Expert Review of Hematology (2014) Vol. 8, Iss. 1, pp. 43-56
Closed Access | Times Cited: 31
A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment
Serena Tseng, Mu-En Lee, Pei‐Chin Lin
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1614-1614
Open Access | Times Cited: 9
What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?
Susan DeWolf, Martin S. Tallman, Jacob M. Rowe, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 29, pp. 4693-4703
Closed Access | Times Cited: 8
Response kinetics and factors predicting survival in core-binding factor leukemia
Prajwal Boddu, Christopher I. Gurguis, David Sanford, et al.
Leukemia (2018) Vol. 32, Iss. 12, pp. 2698-2701
Closed Access | Times Cited: 27
Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Kazimierz Hałaburda, Myriam Labopin, Audrey Mailhol, et al.
Haematologica (2019) Vol. 105, Iss. 6, pp. 1723-1730
Open Access | Times Cited: 25
Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
Celalettin Üstün, Elizabeth A. Morgan, Erica E. M. Moodie, et al.
Cancer Medicine (2018) Vol. 7, Iss. 9, pp. 4447-4455
Open Access | Times Cited: 20
Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia
Na Lin, Wei Fu, Chen Zhao, et al.
Biochemical and Biophysical Research Communications (2017) Vol. 494, Iss. 1-2, pp. 270-277
Open Access | Times Cited: 19
Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription
Alessandro Beghini
Cancers (2019) Vol. 11, Iss. 12, pp. 1973-1973
Open Access | Times Cited: 18
Detection of KIT mutations in core binding factor acute myeloid leukemia
Passant Badr, Ghada M. El‐Sayed, Dalia Negm Eldin, et al.
Leukemia Research Reports (2018) Vol. 10, pp. 20-25
Open Access | Times Cited: 17
Core binding factor acute myeloid leukemia: Advances in the heterogeneity of KIT, FLT3, and RAS mutations (Review)
Xi Quan, Jianchuan Deng
Molecular and Clinical Oncology (2020) Vol. 13, Iss. 2, pp. 95-100
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top